Similar articles

• Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.

  Piddock LJ, Jin YF, Turner HL. Piddock LJ, et al. J Antimicrob Chemother. 1993 Jan;31(1):89-103. doi: 10.1093/jac/31.1.89. J Antimicrob Chemother. 1993. PMID: 8383105
• Evolution of beta-lactamase inhibitors.

  Rolinson GN. Rolinson GN. Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727. Rev Infect Dis. 1991. PMID: 1656513 Review.
• Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.

  Qadri SM, Ueno Y, Cunha BA. Qadri SM, et al. Chemotherapy. 1996 Sep-Oct;42(5):334-42. doi: 10.1159/000239464. Chemotherapy. 1996. PMID: 8874972
• Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase.

  Easton CJ, Knowles JR. Easton CJ, et al. Antimicrob Agents Chemother. 1984 Sep;26(3):358-63. doi: 10.1128/AAC.26.3.358. Antimicrob Agents Chemother. 1984. PMID: 6095753 Free PMC article.
• New β-lactam antibiotics and β-lactamase inhibitors.

  Bush K, Macielag MJ. Bush K, et al. Expert Opin Ther Pat. 2010 Oct;20(10):1277-93. doi: 10.1517/13543776.2010.515588. Expert Opin Ther Pat. 2010. PMID: 20839927 Review.